A scientific team looks at the progress and challenges in the research and development of brain implants. New achievements in the field of this technology are seen as a source of hope for many ...
Sionna Therapeutics aims to raise $100 million in an IPO for cystic fibrosis drugs, backed by venture capital, targeting a ...
MSD and Eisai’s trial saw mixed success with its two primary endpoints, seeing success in progression-free survival, but ...
8h
In a viewpoint paper recently published in the journal The Lancet Digital Health, a team led by Stanisa Raspopovic from ...
Read about the UK nursing regulator's five “key lines of enquiry” for the next phase of its pre-registration practice ...
Keytruda (pembrolizumab) plus Lenvima (lenvatinib) and chemotherapy improved progression-free survival but did not achieve ...
Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and ...
The unsuccessful Phase III results are the latest to suggest that the blockbuster cancer drug is finally bumping up against ...
Co., Inc. (NYSE:MRK) and Eisai Co., Ltd. (TYO:4523) have announced the latest outcomes from their Phase 3 LEAP-015 trial, ...
President and Acting President of UT Health San Antonio, Taylor Eighmy, has appointed Francisco G. Cigarroa, M.D., as the Senior Executive Vice President for Health Affairs & Health System at UT ...
As we reflect on 2024, I am proud to share the remarkable progress Atossa Therapeutics has made in advancing our mission to address significant unmet needs in breast cancer prevention and treatment.
One of the earliest proponents of evidence-based medicine, Professor David Sackett, wrote, “Good doctors use both individual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback